Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Next Previous
X
Search
Trial Profile

Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 29 Mar 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 22 Jun 2010 Results have been published in the Journal of Acquired Immune Deficiency Syndromes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top